AbbVie Inc., a biopharmaceutical company, has successfully completed the acquisition of ImmunoGen, Inc., a leader in antibody-drug conjugates for cancer treatment, as of February 12, 2024. This follows the Merger Agreement entered into on November 30, 2023. In accordance with the terms of the Merger Agreement, AbbVie has assumed the ImmunoGen Amended and Restated 2018 Employee, Director and Consultant Equity Incentive Plan and the ImmunoGen Inducement Equity Incentive Plan, as amended. Outstanding restricted stock unit awards under these plans have been converted into awards for AbbVie common stock. The company has filed a Registration Statement on Form S-8 with the Securities and Exchange Commission to register the common stock issuable upon the settlement of the converted awards. This move is part of AbbVie's strategic efforts to expand its oncology portfolio and leverage ImmunoGen's expertise in the development of targeted therapies for cancer patients.

AbbVie Inc., a biopharmaceutical company, has successfully completed the acquisition of ImmunoGen, Inc., a leader in antibody-drug conjugates for cancer treatment, as of February 12, 2024. This follows the Merger Agreement entered into on November 30, 2023. In accordance with the terms of the Merger Agreement, AbbVie has assumed the ImmunoGen Amended and Restated 2018 Employee, Director and Consultant Equity Incentive Plan and the ImmunoGen Inducement Equity Incentive Plan, as amended. Outstanding restricted stock unit awards under these plans have been converted into awards for AbbVie common stock. The company has filed a Registration Statement on Form S-8 with the Securities and Exchange Commission to register the common stock issuable upon the settlement of the converted awards. This move is part of AbbVie's strategic efforts to expand its oncology portfolio and leverage ImmunoGen's expertise in the development of targeted therapies for cancer patients.